Limits...
Ability of PITX2 methylation to predict survival in patients with prostate cancer.

Li JZ, Zhang Y, Wen B, Li M, Wang YJ - Onco Targets Ther (2015)

Bottom Line: After reviewing the literature to identify likely candidate genes, we assembled a case-control cohort (in a 1:2 ratio) to explore the distribution of PITX2, WNT5a, SPARC, EPB41L3, and TPM4 methylation levels.The methylation possibility of each of the candidate genes were maximized.Methylation of SPARC was found to be able to distinguish between benign prostate hyperplasia and prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China ; Department of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, People's Republic of China.

ABSTRACT

Background: The aim of this study was to explore whether candidate gene methylation can effectively predict death from prostate cancer.

Methods: After reviewing the literature to identify likely candidate genes, we assembled a case-control cohort (in a 1:2 ratio) to explore the distribution of PITX2, WNT5a, SPARC, EPB41L3, and TPM4 methylation levels. The case group comprised 45 patients with a Gleason score ≤7 who had died as a result of prostate cancer, and the control group comprised 90 current prostate cancer patients or those who died of other causes. The methylation possibility of each of the candidate genes were maximized. Univariate conditional logistic was applied for data analysis and to evaluate prediction efficiency of gene methylation on prostate cancer.

Results: The results indicated that a raised level of PITX2 methylation increased the likelihood of death due to prostate cancer by 10% (odds ratio 1.56, 95% confidence interval 1.17-2.08; P=0.005). Methylation of SPARC was found to be able to distinguish between benign prostate hyperplasia and prostate cancer.

Conclusion: Methylation of PITX2 is an effective biomarker to predict death from prostate cancer, particularly in patients with a low Gleason score.

No MeSH data available.


Related in: MedlinePlus

Methylation level of each gene in benign prostatic hyperplasia (gray) and prostatic cancer (black).Notes: Each position of value boxplot represents the 5th, 25th, 50th, 75th, and 95th percentiles. The white color represents the gene in normal individuals.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664542&req=5

f1-ott-8-3507: Methylation level of each gene in benign prostatic hyperplasia (gray) and prostatic cancer (black).Notes: Each position of value boxplot represents the 5th, 25th, 50th, 75th, and 95th percentiles. The white color represents the gene in normal individuals.

Mentions: Figure 1 shows the methylation levels of the genes of interest in tissue from ten cases of prostate cancer and ten cases of benign prostatic hyperplasia. The methylation levels of EPB41L3, SPARC, PITX2, WNT5a, miR-23b, TOP2a, and CDC20 genes in the cancer tissue were significantly higher than those in the benign prostatic hyperplasia; the most obvious difference between the two types of tissue was in SPARC (P=0.0002, area under the curve 1.0). Methylation levels for CDC20, TOP2A, and CTNNB1 were relatively lower, <5%, and this low level may be due to the reduced accuracy of pyrosequencing that is caused by measurement error. At the other end of the spectrum, methylation levels of miR-23b and LINE1 were higher in all cancer detected samples. The maximum variation between cancer tissue and benign prostatic hyperplastic tissue can be as high as 10% to 20%.


Ability of PITX2 methylation to predict survival in patients with prostate cancer.

Li JZ, Zhang Y, Wen B, Li M, Wang YJ - Onco Targets Ther (2015)

Methylation level of each gene in benign prostatic hyperplasia (gray) and prostatic cancer (black).Notes: Each position of value boxplot represents the 5th, 25th, 50th, 75th, and 95th percentiles. The white color represents the gene in normal individuals.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664542&req=5

f1-ott-8-3507: Methylation level of each gene in benign prostatic hyperplasia (gray) and prostatic cancer (black).Notes: Each position of value boxplot represents the 5th, 25th, 50th, 75th, and 95th percentiles. The white color represents the gene in normal individuals.
Mentions: Figure 1 shows the methylation levels of the genes of interest in tissue from ten cases of prostate cancer and ten cases of benign prostatic hyperplasia. The methylation levels of EPB41L3, SPARC, PITX2, WNT5a, miR-23b, TOP2a, and CDC20 genes in the cancer tissue were significantly higher than those in the benign prostatic hyperplasia; the most obvious difference between the two types of tissue was in SPARC (P=0.0002, area under the curve 1.0). Methylation levels for CDC20, TOP2A, and CTNNB1 were relatively lower, <5%, and this low level may be due to the reduced accuracy of pyrosequencing that is caused by measurement error. At the other end of the spectrum, methylation levels of miR-23b and LINE1 were higher in all cancer detected samples. The maximum variation between cancer tissue and benign prostatic hyperplastic tissue can be as high as 10% to 20%.

Bottom Line: After reviewing the literature to identify likely candidate genes, we assembled a case-control cohort (in a 1:2 ratio) to explore the distribution of PITX2, WNT5a, SPARC, EPB41L3, and TPM4 methylation levels.The methylation possibility of each of the candidate genes were maximized.Methylation of SPARC was found to be able to distinguish between benign prostate hyperplasia and prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China ; Department of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, People's Republic of China.

ABSTRACT

Background: The aim of this study was to explore whether candidate gene methylation can effectively predict death from prostate cancer.

Methods: After reviewing the literature to identify likely candidate genes, we assembled a case-control cohort (in a 1:2 ratio) to explore the distribution of PITX2, WNT5a, SPARC, EPB41L3, and TPM4 methylation levels. The case group comprised 45 patients with a Gleason score ≤7 who had died as a result of prostate cancer, and the control group comprised 90 current prostate cancer patients or those who died of other causes. The methylation possibility of each of the candidate genes were maximized. Univariate conditional logistic was applied for data analysis and to evaluate prediction efficiency of gene methylation on prostate cancer.

Results: The results indicated that a raised level of PITX2 methylation increased the likelihood of death due to prostate cancer by 10% (odds ratio 1.56, 95% confidence interval 1.17-2.08; P=0.005). Methylation of SPARC was found to be able to distinguish between benign prostate hyperplasia and prostate cancer.

Conclusion: Methylation of PITX2 is an effective biomarker to predict death from prostate cancer, particularly in patients with a low Gleason score.

No MeSH data available.


Related in: MedlinePlus